317 Results for "

CDK-4

" in MedChemExpress (MCE) Product Catalog:
Products (317)

317 Results for "CDK-4" in MCE Product Catalog:

5
5 Cited Publications
Art. -Nr.: HY-18629
CAS. Nr.: 377090-84-1
Target:  

CDK Autophagy Apoptosis

Forschungsgebiete:  

Cancer

SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-111556
CAS. Nr.: 2361493-16-3
Reinheit:  ≥98.0%
Target:  

PROTACs CDK Apoptosis

Forschungsgebiete:  

Cancer

BSJ-03-123 is a selective PROTAC degrader of CDK6. BSJ-03-123 degrades CDK6, thereby inhibiting Rb S780 phosphorylation and inducing G1 phase arrest, while remodeling cell cycle and transcriptional signaling, with no effect on CDK4-dependent cancer cells. BSJ-03-123 reduces CDK6 protein levels in mouse ovarian tissues, increases the proportion of primordial follicles, and induces granulosa cell apoptosis, without impairing the ability of oocytes to resume meiosis and mature to the MII stage. BSJ-03-123 alleviates uveitis by blocking the HDACs-CDK6/ID2 axis. BSJ-03-123 can be used in studies related to acute myeloid leukemia, mantle cell lymphoma and autoimmune uveitis .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-18299A
CAS. Nr.: 212844-53-6
Synonyms: NG-60
Target:  

CDK Autophagy Apoptosis

Forschungsgebiete:  

Cancer

Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-114177
CAS. Nr.: 2185857-97-8
Reinheit:  99.91%
Synonyms: PF-06873600
Target:  

CDK

Forschungsgebiete:  

Cancer

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-11001
CAS. Nr.: 718630-59-2
Reinheit:  99.25%
Target:  

CDK Caspase Apoptosis GSK-3

Forschungsgebiete:  

Cancer

PHA-793887 is a CDK inhibitor (with IC50 values of 8 nM for Cdk2, 60 nM for Cdk1, 62 nM for Cdk4, 138 nM for Cdk9). PHA-793887 inhibits purified GSK3β (IC50 79 nM). PHA-793887 reduces the phosphorylation level of nucleophosmin/cdc6, induces G1/G2/M phase arrest, and triggers Apoptosis by activating Caspase-3. PHA-793887 exhibits anticancer activity against leukemia. PHA-793887 can be used in research related to acute leukemia, chronic myeloid leukemia, and advanced/metastatic solid tumors [4].
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-N0805
CAS. Nr.: 26575-95-1
Synonyms: 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma [4] .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-10014
CAS. Nr.: 741713-40-6
Reinheit:  99.57%
Target:  

CDK GSK-3 Apoptosis

Forschungsgebiete:  

Cancer

R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively [4] .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-128669
CAS. Nr.: 1231930-57-6
Reinheit:  99.75%
Synonyms: LSN2839567
Target:  

CDK Drug Metabolite

Forschungsgebiete:  

Cancer

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-16559
CAS. Nr.: 920113-03-7
Synonyms: P276-00
Target:  

CDK Apoptosis

Forschungsgebiete:  

Cancer

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-126534
CAS. Nr.: 2704316-81-2
Reinheit:  98.01%
Synonyms: LSN3106729
Forschungsgebiete:  

Cancer

Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-126534A
CAS. Nr.: 2704316-82-3
Reinheit:  98.18%
Synonyms: LSN3106729 hydrochloride
Forschungsgebiete:  

Cancer

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-15504
CAS. Nr.: 784210-87-3
Reinheit:  99.70%
Target:  

CDK GSK-3 MEK JAK Apoptosis JNK

Forschungsgebiete:  

Neurological Disease Cancer

RGB-286638 is a potent inhibitor of CDK and MAPK9. RGB-286638 inhibits the activities of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3 and p35-CDK5, with IC50 values of 1, 2, 3, 4, 5 and 5 nM, respectively. RGB-286638 inhibits GSK-3β and TAK1, with IC50 values of 3 nM and 5 nM, respectively. RGB-286638 induces caspase-dependent Apoptosis in cells. RGB-286638 delays tumor growth in an orthotopic glioblastoma mouse model. RGB-286638 extends survival in multiple myeloma models. RGB-286638 can be used in research related to glioblastoma and multiple myeloma .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-15504A
CAS. Nr.: 784210-88-4
Reinheit:  98.02%
Target:  

CDK GSK-3 MEK JAK Apoptosis JNK

RGB-286638 free base is a potent inhibitor of CDK and MAPK9. RGB-286638 free base inhibits the activities of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3 and p35-CDK5, with IC50 values of 1, 2, 3, 4, 5 and 5 nM, respectively. RGB-286638 free base inhibits GSK-3β and TAK1, with IC50 values of 3 nM and 5 nM, respectively. RGB-286638 free base induces caspase-dependent Apoptosis in cells. RGB-286638 free base delays tumor growth in an orthotopic glioblastoma mouse model. RGB-286638 free base extends survival in multiple myeloma models. RGB-286638 free base can be used in research related to glioblastoma and multiple myeloma .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-112272
CAS. Nr.: 1628256-23-4
Reinheit:  98.35%
Synonyms: G1T38
Target:  

CDK

Forschungsgebiete:  

Cancer

Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-15889
CAS. Nr.: 1401033-86-0
Reinheit:  99.02%
Target:  

FLT3 CDK

Forschungsgebiete:  

Cancer

AMG 925 is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively.
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-112272A
CAS. Nr.: 2097938-59-3
Reinheit:  98.51%
Synonyms: G1T38 dihydrochloride
Target:  

CDK

Forschungsgebiete:  

Cancer

Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-P80077

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, IP

Reactivity:  

Human, Mouse

loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-13914
CAS. Nr.: 1223498-69-8
Reinheit:  98.09%
Synonyms: BAY 1000394
Target:  

CDK

Forschungsgebiete:  

Cancer

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-111361
CAS. Nr.: 1429515-59-2
Reinheit:  98.72%
Synonyms: LT-171-861
Target:  

CDK FLT3

Forschungsgebiete:  

Cancer

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-116035
CAS. Nr.: 25990-37-8
Reinheit:  99.79%
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .
loading...
    loading...